基本信息 产品详情 公司简介 推荐产品
网站主页 Azintuxizumab
  • (Azintuxizumab)Biosimilar Reference Antibody-GS40052
  • (Azintuxizumab)Biosimilar Reference Antibody-GS40052

1/2

(Azintuxizumab)Biosimilar Reference Antibody-GS40052

Azintuxizumab
300 100μg 起订
湖北 更新日期:2026-04-21

武汉迈思生物科技有限公司

VIP1年
联系人:市场
电话:027-65523427拨打
手机:18007167883 拨打
邮箱:Service@mabnus.com

产品详情:

英文名称:
Azintuxizumab
CAS号:
1826819-57-1
品牌:
Mabnus
产地:
武汉
保存条件:
store at -20°C or -80°C. Avoid repeated freeze.
纯度规格:
>98% by SDS-PAGE
重组:
应用:
ELISA;FC;Functional Assays;IF
种属反应性:
Human
宿主:
Chimeric and Humanised
偶联物:
靶点:
SLAMF7/CD319
免疫原:
SLAMF7/CD319
亚型:
IgG1 - kappa
验证方法:
(Azintuxizumab)Biosimilar Reference Antibody(GS40052) on SDS-PAGE under non-reducing (NR) and reducing (R) condition.

货号:GS40052

Azintuxizumab is a humanized monoclonal antibody typically of the IgG1\kappa isotype, although IgG1 variants are also referenced, indicating its primary role is functional blockade with minimized Fc effector function in its native form. However, its main clinical application is as the antibody component (targeting moiety) of the Antibody-Drug Conjugate (ADC) known as Azintuxizumab vedotin (ABBV-838). In this ADC format, the antibody is linked to a potent cytotoxic payload, usually monomethyl auristatin E (MMAE). Azintuxizumab's role is to bind specifically to its target on malignant cells, allowing the entire ADC complex to be internalized. Once inside the cell, the cytotoxic drug is released, leading to the destruction of the cancer cell. It has been primarily investigated for the treatment of relapsed/refractory multiple myeloma (RRMM).



Azintuxizumab;

公司简介

武汉迈思生物科技有限公司立足于解决行业内功能活性蛋白表达及高亲和力、高灵敏度抗体开发难的痛点,依托自建的两大核心技术平台:哺乳动物细胞蛋白表达平台和单个B细胞抗体开发平台,竭诚为广大科研机构、高等院校、IVD企业、医药企业等提供一站式蛋白表达及抗体开发相关产品和技术服务。

成立日期 (5年)
注册资本 壹佰伍拾万圆人民币
员工人数 10-50人
年营业额 ¥ 1000万-5000万
经营模式 工厂,试剂,定制,服务
主营行业 抗体,蛋白组学

Azintuxizumab相关厂家报价

内容声明
拨打电话 立即询价